Viridian Shares New 52-Week Phase III Trial Data for Active TED
New THRIVE trial data highlight long-term proptosis response with veligrotug in thyroid eye disease patients. Fresh long-term data is showing…
latest posts
New THRIVE trial data highlight long-term proptosis response with veligrotug in thyroid eye disease patients. Fresh long-term data is showing…